- Home
- OABI vs ATLC Comparison
OABI vs ATLC Comparison
Compare OABI & ATLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OABI
- ATLC
- Stock Information
- Founded
- OABI 2012
- ATLC 1996
- Country
- OABI United States
- ATLC United States
- Employees
- OABI N/A
- ATLC N/A
- Industry
- OABI Biotechnology: Pharmaceutical Preparations
- ATLC Finance: Consumer Services
- Sector
- OABI Health Care
- ATLC Finance
- Exchange
- OABI Nasdaq
- ATLC Nasdaq
- Market Cap
- OABI 459.1M
- ATLC 544.2M
- IPO Year
- OABI N/A
- ATLC 1999
- Fundamental
- Price
- OABI $4.53
- ATLC $42.21
- Analyst Decision
- OABI Strong Buy
- ATLC Buy
- Analyst Count
- OABI 4
- ATLC 3
- Target Price
- OABI $9.00
- ATLC $41.00
- AVG Volume (30 Days)
- OABI 349.2K
- ATLC 16.1K
- Earning Date
- OABI 11-12-2024
- ATLC 11-15-2024
- Dividend Yield
- OABI N/A
- ATLC N/A
- EPS Growth
- OABI N/A
- ATLC N/A
- EPS
- OABI N/A
- ATLC 4.21
- Revenue
- OABI $21,714,000.00
- ATLC $362,247,000.00
- Revenue This Year
- OABI N/A
- ATLC N/A
- Revenue Next Year
- OABI $71.78
- ATLC $12.76
- P/E Ratio
- OABI N/A
- ATLC $9.97
- Revenue Growth
- OABI N/A
- ATLC 3.83
- 52 Week Low
- OABI $3.56
- ATLC $23.10
- 52 Week High
- OABI $6.72
- ATLC $42.55
- Technical
- Relative Strength Index (RSI)
- OABI 73.77
- ATLC 80.95
- Support Level
- OABI $4.04
- ATLC $36.86
- Resistance Level
- OABI $4.87
- ATLC $38.54
- Average True Range (ATR)
- OABI 0.18
- ATLC 1.14
- MACD
- OABI 0.10
- ATLC 0.40
- Stochastic Oscillator
- OABI 86.09
- ATLC 95.27
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. The company focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
About ATLC Atlanticus Holdings Corporation
Atlanticus Holdings Corp invests in the financial services industry. It provides various credit and related financial services and products to or associated with the financially underserved consumer credit market. The operating business segments are the Credit as a Service and the Auto Finance segment. It generates maximum revenue from the Credit as a Service segment.